Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $200,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”).
Related news for (KNBIF)
- Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
- Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
- Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
- Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
- Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel